Issues related to Medicare Part D and prescription drug pricing and patient access, including monitor implementation of related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries. Issues related to pharmacy benefit manager transparency, including related provisions in S. 2973, the Modernizing and Ensuring PBM Accountability Act, H.R. 5378, the Lower Costs, More Transparency Act, H.R. 4822, the Health Care Price Transparency Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act, including provisions to establish new requirements for PBMs in Medicare Part D; and H.R. 5385, the Medicare PBM Accountability Act, including provisions to enhance PBM reporting requirements and reporting drug pricing information to HHS.
Support H. Res. 806, expressing support for the recognition of October 2023, as "World Menopause Awareness Month" and expressing the sense of the House of Representatives regarding global awareness and access to care during the menopausal transition and post-menopause.
Duration: July 1, 2019
to
March 31, 2024
General Issues: Medicare/Medicaid , Health Issues
Spending: about $1,070,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives
Related Foreign Entities:
Astellas Pharma Inc. (Tokyo, JPN); contribution to lobbying: $0; ownership 99%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Ann Jablon Chief of Staff, Rep. Richard Neal.
Chief of Staff, Rep. Richard E. Neal; Legislative Director, Rep. Richard E. Neal; Administrative Assistant, Rep. Richard E. Neal; Executive/ Legislative Assistant, Rep. Richard E. Neal.
Jeffrey Carroll Staff Director House Energy and Commerce Committee; Chief of Staff, Rep. Frank Pallone; Legislative Director, Rep. Frank Pallone; Legislative Assistant, Rep. Frank Pallone.
Aaron Cohen Chief of Staff & Legislative Assistant, Sen. John Ensign; Legislative Aide, Sen. Richard Bryan; Legislative Corresp., Sen. Richard Bryan.
Nick Bouknight Deputy Chief of Staff, Rep. Kevin McCarthy; Deputy Chief of Staff/ Communications Dir., Rep. Kevin McCarthy; Press Sec., Rep. Kevin McCarthy; Press Sec., Rep. Bill Thomas; Deputy Press Sec., Ways and Means Cmte.; Press Asst., Ways and Means Cmte.
Shannon Finley n/a
Michelle Mathy n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
Capitol Counsel, LLC terminated an engagement in which they represented Astellas Pharma US, Inc. on April 20.
Original Filing: 301568366.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing and patient access, including monitor implementation of related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries. Issues related to pharmacy benefit manager transparency, including related provisions in S. 2973, the Modernizing and Ensuring PBM Accountability Act, H.R. 5378, the Lower Costs, More Transparency Act, H.R. 4822, the Health Care Price Transparency Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act, including provisions to establish new requirements for PBMs in Medicare Part D; and H.R. 5385, the Medicare PBM Accountability Act, including provisions to enhance PBM reporting requirements and reporting drug pricing information to HHS.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H. Res. 806, expressing support for the recognition of October 2023, as "World Menopause Awareness Month" and expressing the sense of the House of Representatives regarding global awareness and access to care during the menopausal transition and post-menopause.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 19.
Original Filing: 301530198.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing and patient access, including monitor implementation of related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries. Issues related to pharmacy benefit manager transparency, including related provisions in S. 2973, the Modernizing and Ensuring PBM Accountability Act, H.R. 5378, the Lower Costs, More Transparency Act, H.R. 4822, the Health Care Price Transparency Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act, including provisions to establish new requirements for PBMs in Medicare Part D; and H.R. 5385, the Medicare PBM Accountability Act, including provisions to enhance PBM reporting requirements and reporting drug pricing information to HHS.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H. Res. 806, expressing support for the recognition of October 2023, as "World Menopause Awareness Month" and expressing the sense of the House of Representatives regarding global awareness and access to care during the menopausal transition and post-menopause.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 18, 2023.
Original Filing: 301504351.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing and patient access, including monitor implementation of related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries. Issues related to pharmacy benefit manager transparency, including related provisions in the Modernizing and Ensuring PBM Accountability Act, H.R. 5378, the Lower Costs, More Transparency Act, and H.R. 4822, the Health Care Price Transparency Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 19, 2023.
Original Filing: 301484645.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing and patient access, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 19, 2023.
Original Filing: 301456345.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing and patient access, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435779.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing and patient access, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301416535.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing and patient access, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301389812.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing, including related provisions in H.R. 5376 the Build Back Better Act, including provisions regarding Lowering Prices Through Drug Price Negotiation, establishment of a Drug Price Negotiation Program, and Medicare Inflation Rebates, including related provisions in Sections 139001, 139002, 139101, and 139102, and related provisions in the Senate Finance Committee posted amendment to H.R. 5376.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301371980.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing, including related provisions in H.R. 5376 the Build Back Better Act, including provisions regarding Lowering Prices Through Drug Price Negotiation, establishment of a Drug Price Negotiation Program, and Medicare Inflation Rebates, including related provisions in Sections 139001, 139002, 139101, and 139102, and related provisions in the Senate Finance Committee posted amendment to H.R. 5376.
Coronavirus response efforts, including S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 21, 2022.
Original Filing: 301339025.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing, including related provisions in H.R. 5376 the Build Back Better Act, including provisions regarding Lowering Prices Through Drug Price Negotiation, establishment of a Drug Price Negotiation Program, and Medicare Inflation Rebates, including related provisions in Sections 139001, 139002, 139101, and 139102, and related provisions in the Senate Finance Committee posted amendment to H.R. 5376.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 16, 2021.
Original Filing: 301300541.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing, including related provisions in the Build Back Better Act, Budget Reconciliation Legislative Recommendations Relating to Drug Pricing, including provisions regarding Fair Drug Price Negotiation and Prescription Drug Inflation Rebates, in Subtitle E, Energy and Commerce, and Subtitle J, Ways and Means.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301287945.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing, including related provisions in H.R. 3, the Lower Drug Costs Now Act, and H.R. 19, the Lower Costs, More Cures Act.
Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301264808.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing; Coronavirus response efforts, including related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301242329.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing; Coronavirus response efforts, including related provisions in: (1) H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act; (2) H.R. 6201, the Families First Coronavirus Response Act; and (3) H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 15, 2020.
Original Filing: 301211066.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing; Coronavirus response efforts, including related provisions in: (1) H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act; (2) H.R. 6201, the Families First Coronavirus Response Act; and (3) H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301202233.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing; Coronavirus response efforts, including related provisions in: (1) H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act; (2) H.R. 6201, the Families First Coronavirus Response Act; and (3) H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 17, 2020.
Original Filing: 301170985.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing; Coronavirus response efforts, including related provisions in: (1) H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act; (2) H.R. 6201, the Families First Coronavirus Response Act; and (3) H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121615.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
3rd Quarter, 2019
In Q3, Capitol Counsel, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 24, 2019.
Original Filing: 301080001.xml
Lobbying Issues
Issues related to Medicare Part D and prescription drug pricing.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
3rd Quarter, 2019
Capitol Counsel, LLC filed a lobbying registration on Oct. 21, 2019 to represent Astellas Pharma US, Inc., effective July 1, 2019.
Original Filing: 301077508.xml
Issue(s) they said they’d lobby about: Issues related to Medicare Part D and prescription drug pricing. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...